RxMP Therapeutics, Inc. ("RxMP"), a late pre-clinical stage therapeutics company developing novel therapies for the rapid ...
Partnership unites the ReBalU Protocol, Vivos's sleep platform, and a new test for cells primed for chronic disease, reaching ...
Statistically significant compared with placebo, estimated mean, p<0.0001; p values were not adjusted for multiplicity and formal treatment-by-subgroup interaction testing was not performed "This post ...
Recent U.S. Food and Drug Administration interactions have provided the opportunity to initiate a pivotal expansion of the ...
According to the instruction for appointment of the nomination committee in IRLAB Therapeutics AB, resolved at the annual ...
"The standard treatment for DVT has been anticoagulation and there has not been a meaningful change in standard of care for ...
New proprietary Thykamine ™ 0.1% formulation expands Devonian's clinical development program into supportive oncology, with a ...
(Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the ...
Ultima Genomics, Inc., a developer of ultra-high-throughput sequencing systems, today announced the commercial launch of ...
PRNewswire/ -- bitBiome, Inc. (Headquarters: Tokyo; Representative Director and CEO: Yuji Suzuki) is pleased to announce the ...
The trial met the primary and secondary endpoints with statistically significant placebo-adjusted improvements at Week 3 in ...
Since the interim data cut reported in the accepted manuscript, CAMPX has completed patient enrollment and Last Patient, Last ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results